47th week of 2010 patent applcation highlights part 46 |
Patent application number | Title | Published |
20100298200 | Compounds and assays for controlling Wnt activity - The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions. | 2010-11-25 |
20100298201 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES - The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications. | 2010-11-25 |
20100298202 | BRI POLYPEPTIDES AND REDUCING AB AGGREGATION - This document relates to methods and materials for reducing Aβ aggregation. For example, methods and materials related to the use of BRI polypeptides (e.g., BRI2 polypeptides) and fragments of BRI polypeptides (e.g., a BRI23 polypeptide) to reduce Aβ aggregation in mammals are provided. | 2010-11-25 |
20100298203 | SDF-I-BASED GLYCOSAMINOGLYCAN ANTAGONISTS AND METHODS OF USING SAME - The present invention relates to novel mutants of human stromal cell-derived factor-1 which exhibit increased glycosaminoglycan (GAG) binding affinity and inhibited or down-regulated GPCR activity compared to wild type SDF-1, methods for producing these mutants and to their use for preparing medicaments for the treatment of cancer. | 2010-11-25 |
20100298204 | FOOD MATERIAL FOR PROMOTING THE DIFFERENTIATION OF OSTEOBLAST AND INHIBITING THE DIFFERENTIATION OF OSTEOCLAST - Disclosed is an osteoblast differentiation promoting and osteoclast differentiation inhibiting agent which comprises a milk protein fraction having the following characteristics (1) to (4): (1) the milk protein fraction is derived from milk; (2) the milk protein fraction is a fraction containing a protein component having a molecular weight of 75,000 to 85,000 Daltons; (3) the milk protein fraction has a basic amino acid content of 13 to 15 wt % in the constitutional amino acid composition, and has a basic amino acid/acidic amino acid of 0.5 to 0.7; and (4) the milk protein fraction has an osteoblast differentiation promoting effect and an osteoclast differentiation inhibiting. | 2010-11-25 |
20100298205 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS RELATED TO GASTRIC ACID SECRETION - A method comprising orally administering to a mammal a proton pump inhibitor, or a pharmaceutically acceptable prodrug thereof, and a compound which modulates the activity of the MRP2 or other transporter proteins involved in efflux of a proton pump inhibitor or a prodrug, is disclosed herein, said method being effective for the prevention or treatment of a disease or condition related to gastric acid secretion. This method applied to compounds which both inhibit and stimulate MRP2 activity or activity of other transporter proteins involved in efflux of a proton pump inhibitor or a prodrug. | 2010-11-25 |
20100298206 | HYBRID OLIGOMERS, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention relates to compositions and methods for producing therapeutic oligomeric compounds. In one aspect the invention relates to methods for administering the oligomeric compounds for the treatment and prevention of disease, for example, a fungal infection, bacterial infection, or cancer, in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, pharmacologically active agent or a combination thereof. | 2010-11-25 |
20100298207 | PESTICIDAL PROTEINS AND METHODS FOR THEIR USE - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated toxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:50-96, or the nucleotide sequence set forth in SEQ ID NO:1-47, as well as variants and fragments thereof. | 2010-11-25 |
20100298208 | BIOFILM PREVENTION USING LACTOFERRIN - This invention relates to methods and compositions capable of inhibiting biofilm formation. Specifically, provided herein are methods and compositions using Lactoferrin for the inhibition of biofilm formation. | 2010-11-25 |
20100298209 | COMPOUNDS FOR PREVENTING OR TREATING A VIRAL INFECTION - The invention which is the subject of the present application relates to a compound of structure I: A-B-C for use in the prophylaxis and/or treatment of a viral infection, and in particular for preventing and/or inhibiting viral replication, in which A is a quinoline or a quinoline-type group, B is a single amino acid or a peptide or polypeptide having a given amino acid sequence, C is an O-phenoxy group and the symbol “-” indicates that the entities A, B and C are chemically bonded within the compound I. | 2010-11-25 |
20100298210 | HCV NS3 Protease Inhibitors - The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use treating or preventing HCV infections. | 2010-11-25 |
20100298211 | AXMI-001, AXMI-002, AXMI-030, AXMI-035, AND AXMI-045: TOXIN GENES AND METHODS FOR THEIR USE - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated delta-endotoxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:6-11, or the nucleotide sequence set forth in SEQ ID NO:1-5, as well as variants and fragments thereof. | 2010-11-25 |
20100298212 | Modified Insulin Polypeptides and Their Uses - Modified insulin polypeptides and their uses thereof are provided | 2010-11-25 |
20100298213 | Pharmaceutically Active Insulin Receptor-Modulating Molecules - The invention described herein provides novel pharmaceutically active molecules (including novel peptide derivatives and peptides) that bind to an insulin receptor; compositions comprising such molecules; methods of modulating insulin receptor activity comprising the delivery of such molecules and related insulin-binding molecules (e.g., in the context of treating and/or preventing insulin receptor-related diseases such as diabetes); nucleic acids encoding such peptides; vectors and host cells comprising such nucleic acids; and methods of producing such molecules and compositions. | 2010-11-25 |
20100298214 | TREATMENT OF AUTOIMMUNE DISEASE - The present invention provides compositions, systems, and methods for identifying a patient suffering from and/or susceptible to autoimmune disease who might be likely to respond to treatment with CXCL12 and/or CXCR4 antagonists. The present invention provides novel CXCL12 and/or CXCR4 antagonists, methods of identifying novel CXCL12 and/or CXCR4 antagonists, and methods involving the use of these in the treatment of autoimmune disease. | 2010-11-25 |
20100298215 | SYNTHETIC APOLIPOPROTEIN E MIMICKING POLYPEPTIDES AND METHODS OF USE - The present invention provides methods for using synthetic apolipoprotein E (ApoE)-mimicking peptides. Also disclosed are provides methods for using synthetic apolipoprotein E (ApoE)-mimicking peptides to reduce plasma glucose levels. Methods of using the disclosed apolipoprotein E (ApoE)-mimicking peptides to treat diabetes and diabetic complications are also disclosed. | 2010-11-25 |
20100298216 | Casein Derived Peptides And Uses Thereof in Therapy - Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the oS1 fraction of milk casein. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, hypercholesterolemia, hematological disorders and viral-related diseases. | 2010-11-25 |
20100298217 | CSF-1R MUTANTS - Provided are mutant class III receptor tyrosine kinases (RTKIII) comprising a mutation at the amino acid residue corresponding to the conserved cysteine at residue 432 (C432) or 439 (C439) of a mouse colony-stimulating factor (1) receptor (CSF-IR) precursor having the amino acid sequence of SEQ ID NO: 1, where the mutation is a replacement of the cysteine with an amino acid having an uncharged polar R group. Also provided are mutant RTKIIIs comprising a tyrosine to phenylalanine mutation. Additionally provided are extracellular domains of the above-identified mutant RTKIIIs comprising cysteine to serine mutations. Further provided are stable cell lines of macrophages lacking a native CSF-IR. Also provided are isolated nucleic acids encoding any of the above-described mutant RTKIIIs or extracellular domains. Vectors comprising those nucleic acids are also provided. Additionally provided are methods of preparing the above-identified stable cell lines. Methods of treating a mammal comprising administering the above described extracellular domain to the mammal are also provided. | 2010-11-25 |
20100298218 | Single Branch Heparin-Binding Growth Factor Analogs - A heparin-binding growth factor (HBGF) analog having two substantially similar sequences (homodimeric sequences) branched from a single amino acid residue, where the sequences are analogs of a particular HBGF that binds to a heparin-binding growth factor receptor (HBGFR), or alternatively that bind to a HBGFR without being an analog of any particular HBGF. The homodimeric sequences may be derived from any portion of a HBGF. The synthetic HBGF analog may be an analog of a hormone, a cytokine, a lymphokine, a chemokine or an interleukin, and may bind to any HBGFR. Further provided are preparations for medical devices, pharmaceutical compositions and methods of using the same. | 2010-11-25 |
20100298219 | METHOD OF TREATING CANCER, NEOPLASTIC DISORDERS, AND SYMPTOMS THEREOF WITH COMPOUNDS - The present invention is directed to the use of tissue protective compounds for the prevention, treatment, amelioration or management of cancer, neoplastic diseases, their symptoms and side-effects associated with the treatment of these indications, i.e. chemotherapy or radiation therapy. In particular, these compounds may be chemically modified erythropoietin peptides or recombinant derivatives of erythropoietin, and preferably these compounds lack erythropoietic activity or have substantially reduced erythropoietic activity. | 2010-11-25 |
20100298220 | FIBROBLAST GROWTH FACTOR MUTANTS HAVING IMPROVED FUNCTIONAL HALF-LIFE AND METHODS OF THEIR USE - Mutant fibroblast growth factor (FGF) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the Fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid position 66 of human FGF-1 with a cysteine and/or a specific amino acid substitution of a phenylalanine at a position corresponding to amino acid position 132 of human FGF-1 with a tryptophan (based on the 140 amino acid numbering scheme of human FGF-1) are provided. Other amino acid mutations or substitutions may be combined. Polynucleotide sequences encoding the mutant FGF proteins and host cells containing such polynucleotide sequences are provided. Methods of administering a mutant FGF protein to an individual to treat an ischemic condition or disease or a wound or tissue injury are also provided. | 2010-11-25 |
20100298221 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF - The present invention relates to novel 2-phenoxy-6-phenyl- and 2-phenoxy-6-pyridylnicotinic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prophylaxis of cardiovascular disorders, especially of dyslipidemias, arteriosclerosis and heart failure. | 2010-11-25 |
20100298222 | USE OF AN AGENT THAT RESTORES TISSUE PERFUSION AND OXYGENATION - The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and methods for inhibiting tumor blood vessel growth in subjects. In some embodiments, the presently disclosed methods involve administering to subjects in need thereof a first composition selected from the group consisting of a nitrosylated hemoglobin and an agent that induces nitrosylation of endogenous hemoglobin in the subject and a second composition comprising a hyperoxic gas. In some embodiments, the presently disclosed methods also include treating a tumor with radiation therapy, chemotherapy, photodynamic therapy, immunotherapy, or combinations thereof. Also provided are inhalable gases that can be employed in the presently disclosed methods. | 2010-11-25 |
20100298223 | FIBRINOGEN FOR TREATMENT OF BLEEDING IN TRAUMA AND PLATELET DISORDERS - The present invention relates generally to use of fibrinogen to prevent or treat excessive bleeding in pre-hospital and hospital settings. In particular, the present invention relates to methods for treating bleeding using fibrinogen in individuals suffering from traumatic hemorrhages in pre-hospital settings and in individuals having thrombocytopenia or qualitative platelet disorders. | 2010-11-25 |
20100298224 | USE OF MUTATED ANTITHROMBINS FOR TREATING OR PREVENTING COAGULATION DISORDERS - Use of a mutated antithrombin having substantially no activity, in particular no anticoagulant activity, possibly in association with an anticoagulant, for the preparation of a drug intended for the prevention or treatment of pathologies linked to or associated with coagulation disorders. | 2010-11-25 |
20100298225 | PEPTIDE GAP JUNCTION MODULATORS - Disclosed are peptides that facilitate the intercellular communication mediated by gap junctions. The invention has a wide spectrum of useful applications including use in the treatment of diseases associated with impaired gap junction intracellular communication (GJIC). | 2010-11-25 |
20100298226 | POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME AND USE THEREOF IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH ISCHEMIA - An isolated polynucleotide is disclosed comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence of HIF-1alpha, the polypeptide being stably expressed and constitutively active. Isolated polypeptides encoded by same are also disclosed and uses thereof. | 2010-11-25 |
20100298227 | Treatment of autoimmune conditions with Copolymer 1 and related copolymers - The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal. | 2010-11-25 |
20100298228 | BONE-REINFORCING FOOD MATERIAL - Disclosed is a bone-reinforcing agent which comprises a milk protein fraction having the following properties (1) to (4): (1) the milk protein fraction is derived from milk; (2) the milk protein fraction is a fraction containing a protein component having a molecular weight of 6,000 to 150,000 Daltons; (3) the milk protein fraction has a basic amino acid content of 12 to 14 wt % in the constitutional amino acid composition, and the ratio of the amount of a basic amino acid(s) to the amount of an acidic amino acid(s) is 0.5 to 0.7; and (4) the milk protein fraction has an activity of accelerating the calcification in an osteoblast. | 2010-11-25 |
20100298229 | OSTEOPROTEGERIN - The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis. | 2010-11-25 |
20100298230 | USE OF TRUNCATED CYSTEINE IL28 AND IL29 MUTANTS TO TREAT CANCERS AND AUTOIMMUNE DISORDERS - Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics. | 2010-11-25 |
20100298231 | PMMA BINDING PEPTIDES - Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface. | 2010-11-25 |
20100298232 | Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof - The present invention provides modulators of TNF, particularly peptides and their derivatives, particularly GEP peptides, which antagonize TNF and TNF-mediated responses, activity or signaling. The invention provides methods of antagonizing TNF and the modulation of TNF-mediated diseases or responses, including inflammatory diseases and conditions. Compositions of GEP peptides, including in combination with other inflammatory mediators, are provided. Methods of treatment, alleviation, or prevention of TNF-mediated diseases and inflammatory conditions, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, inflammatory bowel diseases, Chrohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, are provided. | 2010-11-25 |
20100298233 | COMPOSITIONS AND METHODS RELATED TO PROFILING A PLURALITY OF CELLS BASED ON PEPTIDE BINDING - Methods and compositions are described for classifying cells and/or peptides that associate or bind with a particular characteristic pattern to a plurality of cells or cell lines. Aspects of the invention also include the use of peptide(s) having an appropriate binding characteristic to deliver a drug to a cell or cell population. | 2010-11-25 |
20100298234 | Cancer therapeutic agents comprising a ligand for the neuromedin u receptor 2 (fm4) molecule as an active ingredient - The present inventors discovered that the neuromedin U receptor 2 (FM4) molecule is highly expressed in cancer cells such as pancreatic cancer cells. When the present inventors measured the proliferation-suppressing effect of ligands of this molecule against cancer cells, the ligands were found to have cancer cell proliferation-suppressing effects. The present inventors also discovered that this effect was produced by an FM4 molecule-mediated signal. These findings showed that ligands for the neuromedin U receptor 2 (FM4) molecule are effective for the treatment of cancers with enhanced expression of the neuromedin U receptor 2 (FM4) molecule, including pancreatic cancer, as well as for prevention of metastasis. | 2010-11-25 |
20100298235 | Epithelial cell growth promoter - It is intended to provide a novel oligopeptide which can be relatively easily produced, has not only a hair growth-stimulating effect but also an effect of promoting the growth of epithelial cells (for example, skin regeneration) and can easily pass through the horny layer to thereby reach the desired target cells in which its effects are to be exerted. Namely, water-soluble oligopeptides containing a proryl isoleucyl glycyl unit or an isoleucyl glycyl serine unit and having from 3 to 7 amino acids and water-soluble salts thereof. | 2010-11-25 |
20100298236 | SOLUBLE GP130 MUTEINS WITH IMPROVED BINDING ACTIVITY - Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr | 2010-11-25 |
20100298237 | USE OF HDAC INHIBITORS FOR TREATMENT OF CARDIAC RHYTHM DISORDERS - The present invention provides methods of ameliorating or reducing the extent of cardiac arrhythmia disorders, by administering an inhibitor of histone deacetylase enzyme (HDAC). | 2010-11-25 |
20100298238 | NONTOXIC SHIGA-LIKE TOXIN MUTANT COMPOSITIONS AND METHODS - Disclosed are nontoxic mutants of Shiga-like toxin (Stx1 or Stx2), nucleic acids encoding them, compositions containing the mutants and methods of using the mutants in connection with hemolytic euremic syndrome (HUS). Also disclosed are methods of treating HUS using L3 protein fragments, the nontoxic Stx1 or Stx2 mutants, or combinations thereof. | 2010-11-25 |
20100298239 | PEPTIDE WITH MULTIPLE EPITOPES - The present invention relates to peptides comprising multiple MHC Class II-binding T cell epitopes for tolerisation therapy. | 2010-11-25 |
20100298240 | PMMA BINDING PEPTIDES - Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface. | 2010-11-25 |
20100298241 | PMMA BINDING PEPTIDES - Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface. | 2010-11-25 |
20100298242 | MASKING THE TASTE OF COMPOSITONS CONTAINING SALT - The invention relates to the use of sweeteners for masking the salty taste of compositions as well as compositions containing salt and defined sweeteners, the amount of sweeteners being suitable for masking the salty taste of the composition. | 2010-11-25 |
20100298243 | COMBINATION THERAPY WITH SGLT-2 INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS - The present invention is directed to a pharmaceutical composition comprised of one or more SGLT-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class I obesity, class II obesity, class III obesity, visceral obesity and abdominal obesity, and metabolic syndrome. | 2010-11-25 |
20100298244 | COMPOSITION FOR THE PREVENTION AND THE TREATMENT OF HELICOBACTER PYLORI INFECTION - The disclosed item is a composition comprising catechins and sialic acid to provide an effective prevention and treatment for | 2010-11-25 |
20100298245 | Pharmaceutical Composition for the Treatment of IL-8 mediated diseases - A compound of formula (I) can be used for the preparation of a pharmaceutical composition for the treatment, diagnosis or prophylaxis of Interleukin-8 related to viral infections. | 2010-11-25 |
20100298246 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same - Sulfoquinovosylacyl propanediol compounds represented by formula (I): | 2010-11-25 |
20100298247 | PESTICIDE COMPOSITIONS EXHIBITING ENHANCED ACTIVITY - Pest controlling compositions exhibiting enhanced pesticidal activity levels are disclosed. In one embodiment, a composition includes at least one pesticide, at least one proteinaceous material and at least one polymeric material. In this embodiment, the composition exhibits enhanced pesticidal activity levels compared to a composition dissimilar only in not having the at least one proteinaceous material and the at least one polymeric material. Still, alternative embodiment pesticide compositions exhibiting enhanced activity levels are disclosed. | 2010-11-25 |
20100298248 | BIOLOGICALLY ACTIVE MACROLIDES, COMPOSITIONS, AND USES THEREOF - The present invention provides a compound of the formula (I) or (II, wherein R | 2010-11-25 |
20100298249 | PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF AND USE OF SAME - The invention relates to a pharmaceutical or cosmetic composition for topical and/or parenteral application comprising, in a physiologically acceptable medium, at least one retinoid or salts and derivatives thereof, and at least one inhibitor of hyaluronic acid degradation. The invention is of use in particular in human dermatology or in reconstructive surgery. | 2010-11-25 |
20100298250 | COMPOSITIONS AND METHODS FOR EXTRACTING AND USING PHYTOCHEMICALS FOR THE TREATMENT OF INFLUENZA - Methods and compositions for treating at least one symptom of a viral infection, said method of treatment comprising administering to a subject with a least one symptom of a viral infection an effective dosage unit of a composition comprising pomegranate extract. The compositions comprise pomegranate extract comprising polyphenols. The composition is produced by a process comprising providing one or more pomegranate solids selected from the group consisting of a pericarp, inner membrane and seeds, creating a mixture comprising said one or more pomegranate solids in an aqueous solution, heating said mixture to a temperature that permits enzyme catalysis of said pomegranate solids, and removing residual insoluble solid materials from said mixture to provide said pomegranate extract. Compositions containing the extract may be used as a food product, beverage, pharmaceutical preparations, nutritional supplements, vitamin supplements, food additives, and food supplements. | 2010-11-25 |
20100298251 | WOUND-HEALING AGENT CONTAINING MOMORDICAE SEMEN EXTRACT - The present invention relates to Momordicae semen extract having wound-healing efficiencies. In particular, the present invention relates to a wound-healing topical transdermal agent comprising an active ingredient of Momordicae semen extract, which is capable of reducing the time required for the closure and treatment of wounds as confirmed in skin-wound induced animal model. | 2010-11-25 |
20100298252 | METHODS AND COMPOSITIONS FOR OPHTHALMIC TREATMENT OF FUNGAL AND BACTERIAL INFECTIONS - The present invention provides methods and compositions for use in the methods for contacting an eye of a patient with an effective amount of therapeutic composition comprising a pharmaceutically acceptable chelating agent, a pharmaceutically acceptable pH buffering agent, and an antimicrobial agent. | 2010-11-25 |
20100298253 | Pharmaceutical Compositions Comprising Forms of 5-Azacytidine - The invention provides novel polymorphic and pseudopolymorphic crystalline forms of 5-azacytidine, along with methods for preparing said forms, wherein 5-azacytidine is represented by the formula: | 2010-11-25 |
20100298254 | ORGAN ARREST, PROTECTION AND PRESERVATION - The present invention relates to a method for arresting, protecting and/or preserving an organ which includes administering effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) local anaesthetic to a subject in need thereof. | 2010-11-25 |
20100298255 | Methods for providing personalized medicine test ex vivo for hematological neoplasms - Described herein are methods, devices, and compositions for providing personalized medicine tests for hematological neoplasms. In some embodiments, the methods comprise measuring the efficacy of inducing apoptosis selectively in malignant cells using any number of potential alternative combination drug treatments. In some embodiments, the ex vivo testing is measured using a recently extracted patient hematological samples. In other embodiments, the efficacy is measured ex vivo using an automated flow cytometry platform. For example, by using an automated flow cytometry platform, the evaluation of hundreds, or even thousands of drugs and compositions, can be made ex vivo. Thus, alternative polytherapy treatments can be explored. Non-cytotoxic drugs surprisingly induce apoptosis selectively in malignant cells ex vivo. In some embodiments, the methods described herein comprise evaluating non-cytotoxic drugs. | 2010-11-25 |
20100298256 | ANTIVIRAL COMPOUNDS - Lipid-modified phosphodiester nucleoside prodrugs are described herein. The prodrugs can be used to treat viral infections and cancer. | 2010-11-25 |
20100298257 | NUCLEOSIDE PHOSPHORAMIDATES - Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. | 2010-11-25 |
20100298258 | ANALGESIC COMPOSITIONS - Embodiments of the invention relates to pharmaceutical compositions for use in the treatment of pain and inflammation in mammals, including humans, by administering compositions comprising i) an effective amount of an analgesic having an optional anti-inflammatory effect; (ii) an amount of caffeine effective in enhancement of pain relief; and, (iii) an amount of B vitamins effective in enhancement of pain relief. | 2010-11-25 |
20100298259 | PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF AND USE OF SAME - The invention relates to a pharmaceutical or cosmetic composition for topical and/or parenteral application comprising, in a physiologically acceptable medium, at least one retinoid or salts and derivatives thereof, and at least one hyaluronic acid oligomer chosen from compounds containing from 1 to 6 disaccharide units. The invention is of use in particular in human dermatology or in reconstructive surgery. | 2010-11-25 |
20100298260 | NON-ANTICOAGULANT POLYSACCHARIDE COMPOSITIONS - Preparations of polysaccharides lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided. | 2010-11-25 |
20100298261 | EDIBLE COMPOSITIONS FOR LOWERING CHOLESTEROL - The present invention is related to improved compositions for reducing serum total and/or LDL cholesterol levels. The compositions are combinations of dietary fibre and plant sterol. The compositions are used as such or more advantageously in food products and comprise one or several fibres, preferably β-glucan, in combination with one or several plant sterols and/or stanols in their free and/or esterified forms. | 2010-11-25 |
20100298262 | PROCESS FOR THE ULTRAPURIFICATION OF ALGINATES - A process for the ultrapurification of alginates is provided. In particular, the process may be used for microencapsulation in human cell transplants. | 2010-11-25 |
20100298263 | DERIVATIVES OF PARTIALLY DESULPHATED GLYCOSAMINOGLYCANS ENDOWED WITH ANTIANGIOGENIC ACTIVITY AND DEVOID OF ANTICOAGULATING EFFECT - Partially desulfated glycosaminoglycan derivatives are described, particularly heparin, and more particularly formula (I) compounds | 2010-11-25 |
20100298264 | BIODEGRADABLE AND WATER-SOLUBLE HEMOSTATIC MATERIAL AND A METHOD FOR PREPARING THE SAME - A biodegradable and water-soluble hemostatic material is provided. The hemostatic material comprises an oxidized regenerated cellulose salt having a degree of carboxylic acid oxidation not less than 5%, a degree of etherification of 0.2 to 1.2 and a number average molecular weight of 50,000 to 200,000. The hemostatic material according to the present invention offers improved hemostatic effect, absorbability and operability over existing hemostatic products. A method for preparing the hemostatic material is further provided. | 2010-11-25 |
20100298265 | Inclusion complex of raloxifene hydrochloride and beta-cyclodextrin - There is described an inclusion complex of raloxifene hydrochloride and β-cyclodextrin in the solid phase having a specific X-ray powder diffraction spectrum. The invention also relates to a process for obtaining the raloxifene hydrochloride inclusion complex with β-cyclodextrin of the invention. The complex of the invention is employed as a pharmaceutical ingredient in the treatment of osteoporosis, specifically postmenopausal osteoporosis. | 2010-11-25 |
20100298266 | HYDROXYETHYLSTARCH - Described are a hydroxyethylstarch, a process for the preparation thereof, a pharmaceutical formulation containing such a hydroxyethylstarch, and the use of the pharmaceutical formulation for the preparation of a volume replacement, a plasma replacement or a plasma volume expander, as well as the use of the pharmaceutical formulation for maintaining normovolemia and/or for improving the macro- and microcirculation and/or for improving the nutritive oxygen supply and/or for stabilizing hemodynamics and/or for improving the volume efficiency and/or for reducing the plasma viscosity and/or for increasing anemia tolerance and/or for hemodilution, especially for therapeutic hemodilution in disturbed blood supply and arterial, especially peripheral arterial, occlusive diseases. | 2010-11-25 |
20100298267 | AMINOPYRIMIDINAMIDES AS PESTICIDES - The present application relates to novel aminopyrimidinamides, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects. | 2010-11-25 |
20100298268 | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF - The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor. | 2010-11-25 |
20100298269 | PRODRUGS OF CGRP RECEPTOR ANTAGONISTS - Disclosed are prodrug compounds of formula (I) (wherein variables R | 2010-11-25 |
20100298270 | Novel Compounds and Methods of Using Them - Described herein are novel HDAC modulators, formulations containing them and methods of using them. In some embodiments, the HDAC modulators possess specific stereo chemistry. In other embodiments, the compounds described herein are used in the treatment or prevention of histone deacetylase mediated disorders. | 2010-11-25 |
20100298271 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER - Compound of Formula I or a salt thereof for treating cancer, wherein X represents CH or N; R | 2010-11-25 |
20100298272 | PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS, SUGAR ANALOGUES, AND COMPOSITIONS HAVING ANTI-CANCER ACTIVITY CONTAINING THE SAME - A new anticancer compounds of formula (1) Drugs and pharmaceutical compositions to be used in human or veterinary medicine, which include at least one compound of formula (1). A method of treating and/or preventing cancer in a human or an animal using the compound of formula (1) | 2010-11-25 |
20100298273 | LIPID MIXTURE FOR INFANT NUTRITION - The subject invention thus provides a composition comprising at least one triglyceride, at least one phospholipid and at least one poly-unsaturated fatty acids (LC-PUFA); wherein at least about 1% of the LC-PUFA in the composition is conjugated to said at least one phospholipid and uses thereof. | 2010-11-25 |
20100298274 | FAT CONTAINING COMPOSITION - A composition comprises a fat phase wherein the fat phase comprises: more than 10 wt. % DHA and/or EPA or derivatives thereof; or more than 5 wt. % GLA or a derivative thereof; or more than 10 wt. % of GLA, EPA and/or DHA in total or derivatives thereof; and secoisolariciresinol (SECO) or a derivative thereof, with the proviso that when the composition comprises GLA, the composition is substantially free of isoflavones. The composition and mixtures or blends comprising the composition may be used for the treatment of PMS and prostate conditions. | 2010-11-25 |
20100298275 | Methods of and Formulations for Reducing and Inhibiting the Growth of the Concentration of Microbes in Water-Based Fluids and Systems Used with Them - The present invention provides methods and formulations for reducing or inhibiting increase in the concentration of microbes in a water-based fluid. The methods and formulations of the present invention use glutaraldehyde and a hydroxymethyl-substituted phosphorus compound selected from the group consisting of tetrakis(hydroxymethyl)phosphonium salts, C | 2010-11-25 |
20100298276 | THYROID RECEPTOR LIGANDS - Thyroid receptor ligands are provided which have the general formula I | 2010-11-25 |
20100298277 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 2010-11-25 |
20100298278 | INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The invention relates to the substituted 1,2-ethylenediamines of general formula (I), | 2010-11-25 |
20100298279 | Oral Contraceptives to Prevent Pregnancy and Diminish Premenstrual Symptomatology - This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same. | 2010-11-25 |
20100298280 | Compounds for the Modulation of Huntingtin Aggregation, Methods and Means for Identifying Such Compounds - The present invention relates to tetranortriterpenoid compounds and pharmaceutical compositions thereof, which are provided for use in the treatment, diagnosis and/or prevention of trinucleotide repeat disorders (like a polyglutamine diseases, e.g Huntingdon's disease), amyloid diseases, neurodegenerative disease, protein misfolding diseases or tumors. The tetranortriterpenoid compounds of the present invention are further provided for the reduction and/or inhibition of the aggregation of amyloidogenic proteins, preferably of polyglutamine proteins (such as huntingtin) as well as for increasing proteasome activity. The present invention furthermore relates to nucleic acids, comprising the nucleotide sequences of two huntingtin fragments, as well as to cells and kits, which are useful in methods for assessing the aggregation of huntingtin and in methods for identifying compounds, which modulate the aggregation of huntingtin. | 2010-11-25 |
20100298281 | Steroid-Derived Cyclopamine Analogs and Methods for Using the Same in the Prevention or Treatment of Cancer - The present invention relates to steroid-derived cyclopamine analogs and methods for using the same for inhibiting sonic hedgehog signaling and preventing or treating cancer. A method for synthesizing the analogs of the present invention from a steroid is also provided. | 2010-11-25 |
20100298282 | Treatment of Ocular Conditions and the Side-Effects of Glucocorticoids - A compound having glucocorticoid receptor (GR) antagonist activity and a clogP value of less than 5 is useful for the treatment of an ocular condition. Further, a compound having glucocorticoid receptor (GR) antagonist activity is useful, for the treatment of a patient exhibiting side-effects of the administration of a glucocorticosteroid, e.g. wherein the glucocorticosteroid and said compound are administered by different routes. | 2010-11-25 |
20100298283 | PHARMACEUTICAL COMPOSITION FOR ENHANCING IMMUNITY, AND EXTRACT OF PORIA - A pharmaceutical composition is used to enhance immunity of the human body. The composition contains potent components of lanostane compounds. A method is devised to obtain an extract from metabolite, sclerotium, or fermentation product of | 2010-11-25 |
20100298284 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA - Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders. | 2010-11-25 |
20100298285 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof - Bicycloheteroaryl compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others. | 2010-11-25 |
20100298286 | Organic Compounds - The present invention relates to a compound of formula I | 2010-11-25 |
20100298287 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - There is provided a compound of the formula (I′): wherein X is a nitrogen or CRx, Rx is a hydrogen, etc., R | 2010-11-25 |
20100298288 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES - Compounds having the structure of Formula I1 including pharmaceutically acceptable salts of the compounds, are potent CETP (cholesterol ester transfer protein) inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis Atherosclerosis and its clinical consequences, coronary heart disease (CHD), stroke and penpheral vascular disease, represent a truly enormous burden to the health care systems of the industrialized world In formula I, A-B is an arylamide moiety | 2010-11-25 |
20100298289 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS - The present invention concerns heterobicyclic compounds of formula (I) processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 2010-11-25 |
20100298290 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture - The invention is directed to Compounds of Formula I: | 2010-11-25 |
20100298291 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS - Compounds of formula (I) | 2010-11-25 |
20100298292 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF - The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) | 2010-11-25 |
20100298293 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE - The invention relates to novel substituted oxazolidinones, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases, and to the use thereof for producing medicaments for treatment and/or prophylaxis of diseases, especially of thromboembolic disorders. | 2010-11-25 |
20100298294 | KETONE BODIES AND KETONE BODY ESTERS AS BLOOD LIPID LOWERING AGENTS - The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject. Alternatively, compositions comprising racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or combinations thereof can be formulated as nutritional supplements (also referred to as nutritional compositions) or incorporated into therapeutic compositions containing a) anti-hypertensive agents; b) anti-inflammatory agents; c) glucose lowering agents; or d) anti-lipemic agents) which are administered to a subject, optionally in combination with a low fat diet, in order to cause a reduction or lowering of: serum cholesterol levels; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and/or hypertension in treated subjects. Alternatively, compositions disclosed herein can be administered alone, or in combination with other therapeutic agents to prevent or reverse vascular disease. | 2010-11-25 |
20100298295 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS - The invention provides novel pyrimidine derivatives of formula (1) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or anaplastic lymphoma kinase (ALK). | 2010-11-25 |
20100298296 | Oligomer-Tricyclic Conjugates - The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water soluble oligomer. | 2010-11-25 |
20100298297 | Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof - This invention relates to compounds of Formula (I), | 2010-11-25 |
20100298298 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF - The invention relates to quinazolinedione derivatives, processes for the preparation thereof and their therapeutic applications. | 2010-11-25 |
20100298299 | NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS - The present invention relates to new non-peptide derivatives of formula (I), wherein R | 2010-11-25 |